RT Generic
T1 Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist
A1 Cacicedo, Jon
A1 Navarro, Arturo
A1 del Hoyo, Olga
A1 Gomez-Iturriaga, Alfonso
A1 Along, Filippo
A1 Medina, Jose A.
A1 Elicin, Olgun
A1 Skanjeti, Andrea
A1 Giammarile, Francesco
A1 Bilbao, Pedro
A1 Casquero, Francisco
A1 de Bari, Berardino
A1 Dal Pra, Alan
K1 Positron-emission-tomography
K1 Squamous-cell carcinoma
K1 Metabolic tumor volume
K1 Contrast-enhanced ct
K1 Standardized uptake value
K1 Total lesion glycolysis
K1 Unknown primary tumors
K1 Lymph-node metastases
K1 2nd primary tumors
K1 Locally advanced head
AB Squamous cell carcinoma is the most common malignant tumour of the head and neck. The initial TNM staging, the evaluation of the tumour response during treatment, and the long-term surveillance are crucial moments in the approach to head and neck squamous cell carcinoma (HNSCC). Thus, at each of these moments, the choice of the best diagnostic tool providing the more precise and larger information is crucial. Positron emission tomography with fluorine-18 fludeoxyglucose integrated with CT (F-18-FDG-PET/CT) rapidly gained clinical acceptance, and it has become an important imaging tool in routine clinical oncology. However, controversial data are currently available, for example, on the role of F-18-FDG-PET/CT imaging during radiotherapy planning, the prognostic value or its real clinical impact on treatment decisions. In this article, the role of F-18-FDG-PET/CT imaging in HNSCC during pre-treatment staging, radiotherapy planning, treatment response assessment, prognosis and follow-up is reviewed focusing on current evidence and controversial issues. A proposal on how to integrate F-18-FDG-PET/CT in daily clinical practice is also described.
PB British inst radiology
SN 0007-1285
YR 2016
FD 2016-01-01
LK http://hdl.handle.net/10668/19142
UL http://hdl.handle.net/10668/19142
LA en
DS RISalud
RD Apr 10, 2025